The Vyome Story
Vyome Biosciences develops new and breakthrough treatments for refractory and other skin conditions. The treatments target fungal and bacterial skin infections, persistent conditions such as acne and dandruff, and antibiotic-resistant infectious diseases. Since its inception in 2010 by Dr. Shiladitya Sengupta, Dr. Rajesh Gokhale, N. Venkat, and Rajiv Mantri, Vyome has built a robust patent portfolio based on its molecular replacement therapeutics (MRT™) and dual action rational therapeutics (DART™) for a wide range of dermatological indications.
In Conversation with Venkat
Recipe for success
I believe that for a startup to be successful, the following points matter the most:
- Focus on what is the end objective for your business and the activities. It not only motivates the team and channelizes their efforts and contribution in one direction, but also provides an edge to the business by keeping track of direct competition.
- Getting a view of the big picture is very essential for every startup, especially for the management team, because it de-clutters the essential from everything else and places the organization on the path of growth sooner.
- Every startup must quickly realize that while the big picture is very essential for direction, the ‘devil is in the details’ of every activity. Businesses that keep an active eye on the details while not losing sight of the big picture are the ones who scale newer heights of success.
- Startups face challenges not only every day, but on an hourly basis, and the key is to tackle those challenges head-on. The team must always think out of the box and come up with solutions to sail ahead.
Your unique idea
Vyome Biosciences is an innovation-driven company that is re-defining the ‘normal’ of current therapies for diseases we focus on. The model of the business is to provide innovation in drug development while ensuring cost-effectiveness and patient satisfaction. Vyome is targeting a market with the major unmet need of combating microbes that have become resistant to available antibiotics. Vyome thrives on its patented platform technologies, MRT™ and DART™, which help us produce the best quality products with enhanced efficacy profiles.
Vyome is operating in the space of both dermatology and antibiotic-resistant infectious diseases, which has a global market size of more than $70 billion.
Partnership with Kalaari
Kalaari Capital has been one of our most supportive investors during the journey so far. They have provided serious value-addition in fund raising, ideas on commercialization and great support to Vyome overall. Kalaari has also played an important role as a sounding board for cross-industry ideas, which has added to Vyome’s experience and expertise. The complementary skills that come with Kalaari’s executives makes it a great investor for partnership.
Your first meeting
During our first meeting with Kalaari, their executives were very friendly and warm in their approach. They promptly got the big picture and understood the essence of Vyome’s business objectives. They were very understanding in their approach and placed a great deal of emphasis on the Vyome team. Overall, the meeting was a very good experience.